Generic Ycanth Availability
Last updated on Nov 6, 2024.
Ycanth is a brand name of cantharidin topical, approved by the FDA in the following formulation(s):
YCANTH (cantharidin - solution;topical)
-
Manufacturer: VERRICA PHARMS
Approval date: July 21, 2023
Strength(s): 0.7% [RLD]
Has a generic version of Ycanth been approved?
No. There is currently no therapeutically equivalent version of Ycanth available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ycanth. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions, methods and systems for the treatment of cutaneous disorders
Patent 11,052,064
Issued: July 6, 2021
Inventor(s): Davidson Matthew Gene
Assignee(s): Verrica Pharmaceuticals Inc.Devices, systems, methods, and kits for treating cutaneous diseases, such as warts, with a cantharidin formulation are generally described. The cantharidin formulations, described herein, may have many advantages over traditional cantharidin formulations, including removal of highly volatile and corrosive solvents, improved safety, and improved compatibility with common plastics for ease of delivery. The devices, systems, methods, and kits can be used for the precise application of the cantharidin formulation for the treatment of cutaneous diseases and other topical indications. Treatment of cutaneous diseases with cantharidin, using the devices, systems, methods, and/or kits may have many advantages over traditional therapies, including high single application efficacy, lack of scaring, and a mild pain profile.
Patent expiration dates:
- May 28, 2035✓✓
- May 28, 2035✓✓
- May 28, 2035
-
Treatment of cutaneous disorders
Patent 11,147,790
Issued: October 19, 2021
Inventor(s): Welgus Howard & Davidson Matthew Gene & Rieger Jayson Michael
Assignee(s): Verrica Pharmaceuticals Inc.Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.
Patent expiration dates:
- August 22, 2038✓✓
- August 22, 2038✓✓
- August 22, 2038
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 21, 2028 - NEW CHEMICAL ENTITY
More about Ycanth (cantharidin topical)
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical keratolytics
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
